Federated Learning in Renal Tumor Model
Research on the Application of Federated Learning in the Construction of Deep Learning Models for Renal Tumor Imaging
This is a multicenter, retrospective and prospective diagnostic clinical trial evaluating the effectiveness and safety of CascadeDiagnose Renal Tumor CT, an AI-assisted detection system for renal tumors based on contrast-enhanced multiphase CT imaging. The system employs a cascaded deep learning architecture to perform fully automated analysis of multiphase CT images, covering image quality review, lesion detection and segmentation, benign-malignant differentiation, and risk stratification, with traceable evidence chains and interpretable outputs. The study is conducted across six tertiary hospitals in Guangxi, China, utilizing a distributed "data stays on-site, computation moves across centers" federated learning network, which ensures that original patient data remain within each hospital while encrypted intermediate features are shared for cross-center collaborative analysis. A total of at least 3000 patients with renal tumors will be enrolled (approximately 2600 in the retrospective phase and 400 in the prospective phase). The primary effectiveness outcomes include area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). The primary safety outcomes include false negative rate, false positive rate, and adverse events. The study also incorporates a multi-reader, multi-case (MRMC) design to compare the diagnostic performance of the AI system with radiologists of varying seniority, and to evaluate the system's utility in assisting junior radiologists. The findings of this study are expected to provide high-quality clinical evidence for the regulatory approval of this AI-assisted diagnostic system as a Class III medical device.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Hai-qi Liang, MD
- Número de teléfono: 86+18176618137
- Correo electrónico: liahiki@163.com
Copia de seguridad de contactos de estudio
- Nombre: Nai-kai Liao, MD
- Número de teléfono: 86+18776891703
- Correo electrónico: 2546419718@qq.com
Ubicaciones de estudio
-
-
Guangxi
-
Guigang, Guangxi, Porcelana, 537100
- Guigang People's Hospital
-
Contacto:
- Jiale Feng, MD
- Número de teléfono: 86+17695684196
- Correo electrónico: 15498419548@qq.com
-
Guilin, Guangxi, Porcelana, 541002
- Guilin People's Hospital
-
Contacto:
- Ke Qin, MD
- Número de teléfono: 86+15954268457
- Correo electrónico: QINKE541002@163.com
-
Liuzhou, Guangxi, Porcelana, 545006
- Liuzhou People's Hospital
-
Contacto:
- Jianwen Yang, MD
- Número de teléfono: 86+13675215625
- Correo electrónico: JWyang235@163.com
-
Nanning, Guangxi, Porcelana, 530021
- The First Affiliated Hospital of Guangxi Medical University
-
Contacto:
- Ji-wen Cheng, PhD
- Número de teléfono: 86+18776891703
- Correo electrónico: chengjiwen@stu.gxmu.edu.cn
-
Contacto:
- Haiqi Liang, MD
- Número de teléfono: 86+18176618137
- Correo electrónico: liahiki@163.com
-
Sub-Investigador:
- Shenghua Deng, MD
-
Nanning, Guangxi, Porcelana, 530021
- Nanning Second People's Hospital
-
Contacto:
- Yang Xie, MD
- Número de teléfono: 86+18346826751
- Correo electrónico: XieYNan@163.com
-
Wuzhou, Guangxi, Porcelana, 543002
- Wuzhou Red Cross Hospital
-
Contacto:
- Deyan Ou, MD
- Número de teléfono: 86+18675651254
- Correo electrónico: OudYan1254@163.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
The study population consists of approximately 3,000 patients with pathologically confirmed renal tumors (benign or malignant) who underwent contrast-enhanced CT at ten Guangxi hospitals between January 2019 and June 2026. Cases are consecutively enrolled using a unified time window and strict inclusion/exclusion criteria. Eligible patients must have complete pre-operative contrast-enhanced CT, good image quality, and traceable clinical-pathological data. Exclusions include non-contrast CT only, severe artifacts, prior nephrectomy (except recurrence/residual), and incomplete data. Enrollment targets are 600 cases at the lead site and 300 at each of the nine participating centers.
Descripción
Inclusion Criteria:
- Patients pathologically confirmed as having renal tumors (either benign or malignant) by surgery or biopsy;
- Underwent contrastenhanced renal CT before surgery or treatment;
- CT images are of good quality and clearly depict the renal lesion contour;
- Complete and traceable clinical and pathological data.
Exclusion Criteria:
- Patients who did not undergo contrastenhanced CT before surgery, or only had noncontrast CT;
- CT images with significant motion artifacts, metal artifacts, or excessive noise that impair lesion assessment;
- Lesions too small (maximum diameter <1 mm) or not identifiable on imaging;
- Patients who previously underwent partial or radical nephrectomy for renal tumors (except for recurrent/residual lesions);
- Incomplete clinical data or pathological results.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: CASE_CONTROL
- Perspectivas temporales: OTHER
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Malignant renal tumor
|
|
Benign renal tumor
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Dice Similarity Coefficient for Renal Tumor Segmentation
Periodo de tiempo: The primary outcome will be measured in October 2027, upon completion of model training, final parameter aggregation, and ensemble model establishment, using the test set from the multi-center retrospective cohort.
|
The primary outcome measure is the Dice Similarity Coefficient for renal tumor segmentation on contrast-enhanced CT, comparing the federated learning model against a centralized training model with a non-inferiority margin of Δ = -0.05. This outcome will be assessed at the end of the model training phase using an independent multi-center test set. |
The primary outcome will be measured in October 2027, upon completion of model training, final parameter aggregation, and ensemble model establishment, using the test set from the multi-center retrospective cohort.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Classification Performance Metrics and Heterogeneity Impact Assessment
Periodo de tiempo: Assessed at the completion of the model training phase, approximately 18 months after study initiation, following final aggregation and ensemble construction, using the independent multi-center test set, with center-specific and subtype-specific analyses
|
The secondary outcomes are: (1) classification performance metrics-AUC, accuracy, sensitivity, and specificity-for benign versus malignant renal tumor discrimination, with pathological diagnosis as the reference; and (2) the impact of data heterogeneity on model performance, assessed by comparing Dice coefficients and AUC values across centers and pathological subtypes. All secondary outcomes will be evaluated at the completion of the model training phase, approximately 18 months after study initiation, after the final federated aggregation and ensemble model construction, using the independent multi-center test set, with center-specific and subtype-specific analyses performed thereafter. |
Assessed at the completion of the model training phase, approximately 18 months after study initiation, following final aggregation and ensemble construction, using the independent multi-center test set, with center-specific and subtype-specific analyses
|
Colaboradores e Investigadores
Investigadores
- Director de estudio: Min Qin, MD, First Affiliated Hospital of Guangxi Medical University
Publicaciones y enlaces útiles
Publicaciones Generales
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
- Bex A, Ghanem YA, Albiges L, Bonn S, Campi R, Capitanio U, Dabestani S, Hora M, Klatte T, Kuusk T, Lund L, Marconi L, Palumbo C, Pignot G, Powles T, Schouten N, Tran M, Volpe A, Bedke J. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update. Eur Urol. 2025 Jun;87(6):683-696. doi: 10.1016/j.eururo.2025.02.020. Epub 2025 Mar 20.
- Xi IL, Zhao Y, Wang R, Chang M, Purkayastha S, Chang K, Huang RY, Silva AC, Vallieres M, Habibollahi P, Fan Y, Zou B, Gade TP, Zhang PJ, Soulen MC, Zhang Z, Bai HX, Stavropoulos SW. Deep Learning to Distinguish Benign from Malignant Renal Lesions Based on Routine MR Imaging. Clin Cancer Res. 2020 Apr 15;26(8):1944-1952. doi: 10.1158/1078-0432.CCR-19-0374. Epub 2020 Jan 14.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Neoplasias por tipo histológico
- Neoplasias Glandulares y Epiteliales
- Adenocarcinoma
- Neoplasias Urológicas
- Carcinoma
- Neoplasias Renales
- Carcinoma De Célula Renal
Otros números de identificación del estudio
- 2026-S0835
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Individual Participant Data (IPD) will not be shared in this study. The primary reasons are threefold: (1) strict legal restrictions under China's Data Security Law and Personal Information Protection Law prohibit cross-institutional transfer of raw medical data without explicit consent; (2) as a retrospective study spanning several years, obtaining renewed consent from all participants is practically infeasible; and (3) the core federated learning framework inherently eliminates the need for IPD sharing-only encrypted model parameters are transmitted, while raw CT images and clinical data remain securely stored at each participating center. This design fully protects patient privacy, complies with all regulatory requirements, and ensures the study's collaborative objectives are achieved without ever exposing individual-level data.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .